Patents by Inventor Satish Pejaver
Satish Pejaver has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220023238Abstract: A process for minimizing formation of a highest degradation product during moist heat sterilization of a drug solution of an oxidation susceptible active pharmaceutical ingredient (API) is provided, wherein the water is not deoxygenated and a nitrogen blanket is not used during formulation, or the formulation is stored in ambient conditions in the polymer bag and autoclaved. The highest degradation product in the parenteral drug product is less than 0.1% by weight of a labeled amount of the oxidation susceptible API in the parenteral drug product.Type: ApplicationFiled: October 7, 2021Publication date: January 27, 2022Inventors: Tushar Hingorani, Tushar Malkan, Sasank Kunadharaju, Satish Pejaver
-
Publication number: 20200330411Abstract: A process for minimizing formation of a highest degradation product during moist heat sterilization of a drug solution of an oxidation susceptible active pharmaceutical ingredient (API) is provided, wherein the water is not deoxygenated and a nitrogen blanket is not used during formulation, or the formulation is stored in ambient conditions in the polymer bag and autoclaved. The highest degradation product in the parenteral drug product is less than 0.1% by weight of a labeled amount of the oxidation susceptible API in the parenteral drug product.Type: ApplicationFiled: June 30, 2020Publication date: October 22, 2020Inventors: Tushar Hingorani, Tushar Malkan, Sasank Kunadharaju, Satish Pejaver
-
Patent number: 10251891Abstract: A liquid pharmaceutical compositions comprising Aprepitant is preferably prepared as an oral suspension dosage form for the prevention and control of acute and delayed chemotherapy induced nausea and vomiting, and/or for prevention of postoperative nausea and vomiting.Type: GrantFiled: October 25, 2016Date of Patent: April 9, 2019Assignee: InnoPharma, Inc.Inventors: Udaya Toti, Shyamprasad Mukundan, Sasank Chaitanya Kunadharaju, Tushar Hingorani, Kumaresh Soppimath, Satish Pejaver, Navneet Puri
-
Publication number: 20190060393Abstract: The invention relates to pharmaceutical compositions that provide improved solubility and stability for peptide epoxy ketones. More specifically, the invention relates to pharmaceutical compositions comprising the peptide epoxy ketone proteasome inhibitor carfilzomib.Type: ApplicationFiled: September 7, 2018Publication date: February 28, 2019Inventors: Ketan Hippalgaonkar, Kumaresh Soppimath, Satish Pejaver, Navneet Puri
-
Publication number: 20190029979Abstract: A process for minimizing formation of a highest degradation product during moist heat sterilization of a drug solution of an oxidation susceptible active pharmaceutical ingredient (API) is provided, wherein the water is not deoxygenated and a nitrogen blanket is not used during formulation, or the formulation is stored in ambient conditions in the polymer bag and autoclaved. The highest degradation product in the parenteral drug product is less than 0.1% by weight of a labeled amount of the oxidation susceptible API in the parenteral drug product.Type: ApplicationFiled: January 23, 2017Publication date: January 31, 2019Inventors: Tushar HINGORANI, Tushar MALKAN, Sasank KUNADHARAJU, Satish PEJAVER
-
Patent number: 9968614Abstract: An aqueous stable and ready-to-use formulation of aprepitant is prepared. Especially preferred formulations comprise a synergistic combination of a co-solvent and a surfactant and may further include a secondary co-solvent. Among other advantages of contemplated formulations, aprepitant is dissolved at high concentrations and remains dissolved and stable, even over prolonged periods of time.Type: GrantFiled: January 30, 2017Date of Patent: May 15, 2018Assignee: InnoPharma, Inc.Inventors: Tushar Hingorani, Kumaresh Soppimath, Satish Pejaver, Navneet Puri
-
Patent number: 9801859Abstract: A lyophilized bendamustine composition consisting of bendamustine hydrochloride, an aqueous solvent, and optionally an excipient, and a method of preparation thereof for treating a condition in a subject are provided. The aqueous solvent includes, for example, water, an acid, a base, or a salt, etc. The excipient includes at least one cryoprotectant, for example, sucrose, trehalose, mannitol, etc. A pre-lyophilization bendamustine composition is lyophilized, for example, by freezing, primary drying, annealing, secondary drying, condensed cooling and evacuation at preset temperatures to obtain the lyophilized bendamustine composition as a cake, a powder, or a solid concentrate. The lyophilized bendamustine composition is free of a non-aqueous solvent. Reconstitution is performed by mixing the lyophilized bendamustine composition with an aqueous solvent for about 30 seconds to 300 seconds. The reconstituted bendamustine product containing about 0.2 wt % to about 2.Type: GrantFiled: September 18, 2013Date of Patent: October 31, 2017Assignee: InnoPharma Licensing, LLCInventors: Udaya Toti, Kumaresh Soppimath, Rekha Nayak, Satish Pejaver, Navneet Puri
-
Publication number: 20170202901Abstract: The invention relates to pharmaceutical compositions that provide improved solubility and stability for peptide epoxy ketones. More specifically, the invention relates to pharmaceutical compositions comprising the peptide epoxy ketone proteasome inhibitor carfilzomib.Type: ApplicationFiled: April 4, 2017Publication date: July 20, 2017Applicant: InnoPharma, Inc.Inventors: Ketan Hippalgaonkar, Kumaresh Soppimath, Satish Pejaver, Navneet Puri
-
Publication number: 20170136027Abstract: An aqueous stable and ready-to-use formulation of aprepitant is prepared. Especially preferred formulations comprise a synergistic combination of a co-solvent and a surfactant and may further include a secondary co-solvent. Among other advantages of contemplated formulations, aprepitant is dissolved at high concentrations and remains dissolved and stable, even over prolonged periods of time.Type: ApplicationFiled: January 30, 2017Publication date: May 18, 2017Inventors: Tushar Hingorani, Kumaresh Soppimath, Satish Pejaver, Navneet Puri
-
Patent number: 9636376Abstract: The invention relates to pharmaceutical compositions that provide improved solubility and stability for peptide epoxy ketones. More specifically, the invention relates to pharmaceutical compositions comprising the peptide epoxy ketone proteasome inhibitor carfilzomib.Type: GrantFiled: September 10, 2013Date of Patent: May 2, 2017Assignee: InnoPharma, Inc.Inventors: Ketan Hippalgaonkar, Kumaresh Soppimath, Satish Pejaver, Navneet Puri
-
Publication number: 20170035774Abstract: A liquid pharmaceutical compositions comprising Aprepitant is preferably prepared as an oral suspension dosage form for the prevention and control of acute and delayed chemotherapy induced nausea and vomiting, and/or for prevention of postoperative nausea and vomiting.Type: ApplicationFiled: October 25, 2016Publication date: February 9, 2017Inventors: Udaya Toti, Shyamprasad Mukundan, Sasank Chaitanya Kunadharaju, Tushar Hingorani, Kumaresh Soppimath, Satish Pejaver, Navneet Puri
-
Patent number: 9180093Abstract: Multi-dose formulations for bortezomib are presented in which bortezomib has significantly improved stability. Especially preferred formulations include those in which bortezomib is in a liquid form suitable for injection, wherein the solvent system predominantly comprises propylene glycol. In other preferred aspects, bortezomib is present as a Lewis donor-acceptor complex with a hetero-bifunctional Lewis base.Type: GrantFiled: August 22, 2012Date of Patent: November 10, 2015Assignee: Innopharma, Inc.Inventors: Kumaresh Soppimath, Satish Pejaver, Kanaiyalal R. Patel, Lakkaraju Dasaradhi, Rama Sodum, Hari Desu, Navneet Puri
-
Patent number: 9107821Abstract: Multi-dose formulations for bortezomib are presented in which bortezomib has significantly improved stability. Especially preferred formulations include those in which bortezomib is in a liquid form suitable for injection, wherein the solvent system predominantly comprises propylene glycol. In other preferred aspects, bortezomib is present as a Lewis donor-acceptor complex with a hetero-bifunctional Lewis base.Type: GrantFiled: August 22, 2012Date of Patent: August 18, 2015Assignee: Innopharma, Inc.Inventors: Kumaresh Soppimath, Satish Pejaver, Kanaiyalal R. Patel, Lakkaraju Dasaradhi, Rama Sodum, Hari Desu, Navneet Puri
-
Patent number: 9061037Abstract: Multi-dose formulations for bortezomib are presented in which bortezomib has significantly improved stability. Especially preferred formulations include those in which bortezomib is in a liquid form suitable for injection, wherein the solvent system predominantly comprises propylene glycol. In other preferred aspects, bortezomib is present as a Lewis donor-acceptor complex with a hetero-bifunctional Lewis base.Type: GrantFiled: March 18, 2011Date of Patent: June 23, 2015Assignee: Innopharma, Inc.Inventors: Kumaresh Soppimath, Satish Pejaver, Kanaiyalal R. Patel, Lakkaraju Dasaradhi, Rama Sodum, Hari Desu, Navneet Puri
-
Publication number: 20150099004Abstract: A liquid pharmaceutical compositions comprising Aprepitant is preferably prepared as an oral suspension dosage form for the prevention and control of acute and delayed chemotherapy induced nausea and vomiting, and/or for prevention of postoperative nausea and vomiting.Type: ApplicationFiled: October 8, 2014Publication date: April 9, 2015Inventors: Udaya Toti, Shyamprasad Mukundan, Sasank Chaitanya Kunadharaju, Tushar Hingorani, Kumaresh Soppimath, Satish Pejaver, Navneet Puri
-
Publication number: 20140303254Abstract: A process for minimizing formation of a highest degradation product during moist heat sterilization of a drug solution of an oxidation susceptible active pharmaceutical ingredient is provided. The oxidation susceptible active pharmaceutical ingredient is mixed with excipients and deoxygenated water to prepare a non-sterile drug solution. The non-sterile drug solution is filled into a moist heat sterilizable flexible infusion bag. The flexible infusion bag with the non-sterile drug solution is terminally moist heat sterilized at a preset air overpressure between about 0.2 bar to about 1.2 bar to obtain a parenteral drug product. The highest degradation product in the parenteral drug product is less than 0.5% by weight of a labeled amount of the oxidation susceptible active pharmaceutical ingredient in the parenteral drug product.Type: ApplicationFiled: April 5, 2014Publication date: October 9, 2014Inventors: Tushar Hingorani, Kumaresh Soppimath, Rekha Nayak, Tushar Malkan, Satish Pejaver, Navneet Puri
-
Publication number: 20140080880Abstract: A lyophilized bendamustine composition consisting of bendamustine hydrochloride, an aqueous solvent, and optionally an excipient, and a method of preparation thereof for treating a condition in a subject are provided. The aqueous solvent includes, for example, water, an acid, a base, or a salt, etc. The excipient includes at least one cryoprotectant, for example, sucrose, trehalose, mannitol, etc. A pre-lyophilization bendamustine composition is lyophilized, for example, by freezing, primary drying, annealing, secondary drying, condensed cooling and evacuation at preset temperatures to obtain the lyophilized bendamustine composition as a cake, a powder, or a solid concentrate. The lyophilized bendamustine composition is free of a non-aqueous solvent. Reconstitution is performed by mixing the lyophilized bendamustine composition with an aqueous solvent for about 30 seconds to 300 seconds. The reconstituted bendamustine product containing about 0.2 wt % to about 2.Type: ApplicationFiled: September 18, 2013Publication date: March 20, 2014Applicant: InnoPharma, Inc.Inventors: Udaya Toti, Kumaresh Soppimath, Rekha Nayak, Satish Pejaver, Navneet Puri
-
Publication number: 20140073583Abstract: The invention relates to pharmaceutical compositions that provide improved solubility and stability for peptide epoxy ketones. More specifically, the invention relates to pharmaceutical compositions comprising the peptide epoxy ketone proteasome inhibitor carfilzomib.Type: ApplicationFiled: September 10, 2013Publication date: March 13, 2014Applicant: InnoPharma, Inc.Inventors: Ketan Hippalgaonkar, Kumaresh Soppinath, Satish Pejaver, Navneet Puri
-
Publication number: 20130317016Abstract: An aqueous stable and ready-to-use formulation of aprepitant is prepared. Especially preferred formulations comprise a synergistic combination of a co-solvent and a surfactant and may further include a secondary co-solvent. Among other advantages of contemplated formulations, aprepitant is dissolved at high concentrations and remains dissolved and stable, even over prolonged periods of time.Type: ApplicationFiled: May 24, 2013Publication date: November 28, 2013Applicant: Innopharma, Inc.Inventors: Tushar Hingorani, Kumaresh Soppimath, Satish Pejaver, Navneet Puri
-
Publication number: 20120322763Abstract: Multi-dose formulations for bortezomib are presented in which bortezomib has significantly improved stability. Especially preferred formulations include those in which bortezomib is in a liquid form suitable for injection, wherein the solvent system predominantly comprises propylene glycol. In other preferred aspects, bortezomib is present as a Lewis donor-acceptor complex with a hetero-bifunctional Lewis base.Type: ApplicationFiled: August 22, 2012Publication date: December 20, 2012Applicant: INNOPHARMA, INC.Inventors: Kumaresh Soppimath, Satish Pejaver, Kanaiyalal R. Patel, Lakkaraju Dasaradhi, Rama Sodum, Hari Desu, Navneet Puri